Genentech Will Alert Physicians To Raptiva Anemia Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
"Dear Healthcare Provider" letter will address a hemolytic anemia warning stemming from postmarketing surveillance of the plaque psoriasis therapy. A precaution on severe arthritis events also has been added.
You may also be interested in...
Remicade Psoriasis Approval Marks Debut Of Centocor Dermatology Sales Force
J&J subsidiary also anticipates eventually using the sales force for another psoriasis product it has in its pipeline.
Remicade Psoriasis Approval Marks Debut Of Centocor Dermatology Sales Force
J&J subsidiary also anticipates eventually using the sales force for another psoriasis product it has in its pipeline.
Genentech Sends Raptiva “Dear Doctor” Letter To Dermatologists, Nurses
Letter addresses new warning in efalizumab labeling on immune-mediated hemolytic anemia. Two cases of hemolytic anemia were observed in clinical trials and two additional cases were observed in postmarketing adverse event monitoring.